5th Oligonucleotides for CNS Summit
August 27 - 29, 2025 - MA USHanson Wade
info@hansonwade.com
Phone:+1 617 455 4188
With clinical momentum from Eli Lilly's lipidated brain shuttle siRNAs, Alnylam Pharmaceuticals' ALN-APP siRNA, Wave's Phase 1b/2a positive SELECT-HD data, 170+ biotech and 30+ pharma active in the field, and a surge of novel approaches, the oligonucleotide field shows no signs of slowing down. The 5th Oligonucleotides for CNS Summit unites a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs. This August, hear from Alnylam Pharmaceuticals, Denali Therapeutics, Genentech, FDA, Novo Nordisk, Regeneron, Servier, Stoke Therapeutics, Ultragenyx Pharmaceutical and more, to redefine the landscape of oligonucleotide research. Time: 8:30 AM - 4:05 PM